Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis

Amy E. Armstrong, Jamie Dargart, Jennifer Reichek, David O. Walterhouse, Debora Matossian, Richard A. Cohn, Yasmin Gosiengfiao*

*Corresponding author for this work

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Renal failure is a rare complication of neuroblastoma or its therapy. To our knowledge, no reports describe treatment of children with neuroblastoma with chemotherapy in the setting of renal failure and maintenance hemodialysis. We report a 6-year-old child with high-risk neuroblastoma who developed renal failure requiring long-term hemodialysis. She was subsequently treated with 13 cycles of intravenous irinotecan 20mg/m2/day and oral temozolomide 100mg/m2/day for 5 days before disease progression without any dose adjustments, transfusions, febrile neutropenia or diarrhea. This case demonstrates that irinotecan and temozolomide can be safely administered in children with renal failure requiring hemodialysis. Pediatr Blood Cancer 2014;61:949-950.

Original languageEnglish (US)
Pages (from-to)949-950
Number of pages2
JournalPediatric Blood and Cancer
Volume61
Issue number5
DOIs
StatePublished - Jan 1 2014

Fingerprint

irinotecan
temozolomide
Neuroblastoma
Renal Insufficiency
Renal Dialysis
Febrile Neutropenia
Therapeutics
Disease Progression
Diarrhea
Maintenance
Drug Therapy

Keywords

  • Chemotherapy
  • Hemodialysis
  • Irinotecan
  • Neuroblastoma
  • Renal failure
  • Temozolomide

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

@article{a83bbf58e1364826bf752d24627e0fa8,
title = "Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis",
abstract = "Renal failure is a rare complication of neuroblastoma or its therapy. To our knowledge, no reports describe treatment of children with neuroblastoma with chemotherapy in the setting of renal failure and maintenance hemodialysis. We report a 6-year-old child with high-risk neuroblastoma who developed renal failure requiring long-term hemodialysis. She was subsequently treated with 13 cycles of intravenous irinotecan 20mg/m2/day and oral temozolomide 100mg/m2/day for 5 days before disease progression without any dose adjustments, transfusions, febrile neutropenia or diarrhea. This case demonstrates that irinotecan and temozolomide can be safely administered in children with renal failure requiring hemodialysis. Pediatr Blood Cancer 2014;61:949-950.",
keywords = "Chemotherapy, Hemodialysis, Irinotecan, Neuroblastoma, Renal failure, Temozolomide",
author = "Armstrong, {Amy E.} and Jamie Dargart and Jennifer Reichek and Walterhouse, {David O.} and Debora Matossian and Cohn, {Richard A.} and Yasmin Gosiengfiao",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/pbc.24869",
language = "English (US)",
volume = "61",
pages = "949--950",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "5",

}

Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis. / Armstrong, Amy E.; Dargart, Jamie; Reichek, Jennifer; Walterhouse, David O.; Matossian, Debora; Cohn, Richard A.; Gosiengfiao, Yasmin.

In: Pediatric Blood and Cancer, Vol. 61, No. 5, 01.01.2014, p. 949-950.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis

AU - Armstrong, Amy E.

AU - Dargart, Jamie

AU - Reichek, Jennifer

AU - Walterhouse, David O.

AU - Matossian, Debora

AU - Cohn, Richard A.

AU - Gosiengfiao, Yasmin

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Renal failure is a rare complication of neuroblastoma or its therapy. To our knowledge, no reports describe treatment of children with neuroblastoma with chemotherapy in the setting of renal failure and maintenance hemodialysis. We report a 6-year-old child with high-risk neuroblastoma who developed renal failure requiring long-term hemodialysis. She was subsequently treated with 13 cycles of intravenous irinotecan 20mg/m2/day and oral temozolomide 100mg/m2/day for 5 days before disease progression without any dose adjustments, transfusions, febrile neutropenia or diarrhea. This case demonstrates that irinotecan and temozolomide can be safely administered in children with renal failure requiring hemodialysis. Pediatr Blood Cancer 2014;61:949-950.

AB - Renal failure is a rare complication of neuroblastoma or its therapy. To our knowledge, no reports describe treatment of children with neuroblastoma with chemotherapy in the setting of renal failure and maintenance hemodialysis. We report a 6-year-old child with high-risk neuroblastoma who developed renal failure requiring long-term hemodialysis. She was subsequently treated with 13 cycles of intravenous irinotecan 20mg/m2/day and oral temozolomide 100mg/m2/day for 5 days before disease progression without any dose adjustments, transfusions, febrile neutropenia or diarrhea. This case demonstrates that irinotecan and temozolomide can be safely administered in children with renal failure requiring hemodialysis. Pediatr Blood Cancer 2014;61:949-950.

KW - Chemotherapy

KW - Hemodialysis

KW - Irinotecan

KW - Neuroblastoma

KW - Renal failure

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=84895768404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84895768404&partnerID=8YFLogxK

U2 - 10.1002/pbc.24869

DO - 10.1002/pbc.24869

M3 - Article

C2 - 24273036

AN - SCOPUS:84895768404

VL - 61

SP - 949

EP - 950

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 5

ER -